Ad
related to: salarius-pharmaceuticals-llc
Search results
Results From The WOW.Com Content Network
HOUSTON and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and Decoy Therapeutics, Inc., a privately held preclinical biopharmaceutical company engineering the next ...
The remaining will belong to current investors of Salarius Pharmaceuticals. There is also a warrants option for holders of Flex Pharma stock that will allow them an additional 2.4% stake in the ...
Salarius Pharmaceuticals Inc (NASDAQ:SLRX) was trading 0.1% higher from the previous closing price. A Form 4 filing filed with the SEC on Monday, August 17 showed that Exec VP Finance CFO ...
Salarius Pharmaceuticals Inc (NASDAQ: SLRX) has initiated the expansion stage of its ongoing Phase 1/2 clinical trial evaluating its lead candidate seclidemstat in patients with relapsed and ...
Concert Pharmaceuticals focuses on deuterated drugs for various conditions. [18] [19] [20] Concert was acquired by Sun Pharma in March 2023. [21] The company Retrotope discovered and has been developing a deuterated fatty acid RT001 as a treatment for neurodegenerative diseases such as Friedreich's ataxia and infantile neuroaxonal dystrophy.
In 1972, he became President and CEO of Key Pharmaceuticals, which was essentially an insolvent company known for cold and cough remedies. [5] Under his leadership, the company developed sustained-release Theo-Dur ( theophylline ), which became the nation's best-selling asthma remedy at the time, and cardiovascular drug Nitro-Dur .
Mylan Pharmaceuticals was founded as a drug distributor in 1961 by Milan Puskar and Don Panoz. [12] In 1966, the company began manufacturing penicillin G tablets as well as vitamins and other dietary supplements.
Embattled Flex Pharma Inc (NASDAQ: FLKS) announced a deal Friday to merge with privately held Salarius Pharma, an oncology company targeting the epigenetic causes of cancer. Following the closing ...